Q3303676 (Q3303676): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Created claim: summary (P836): The development of optimised tolerance-inducing nanoparticles (“OpToPas”) with improved functional and tolerability profile to bring disease-inducing antigens via the bloodstream to the LSECs (so-called “drug targeting”)., translated_summary) |
||||||||||||||
| Property / summary | |||||||||||||||
The development of optimised tolerance-inducing nanoparticles (“OpToPas”) with improved functional and tolerability profile to bring disease-inducing antigens via the bloodstream to the LSECs (so-called “drug targeting”). (English) | |||||||||||||||
| Property / summary: The development of optimised tolerance-inducing nanoparticles (“OpToPas”) with improved functional and tolerability profile to bring disease-inducing antigens via the bloodstream to the LSECs (so-called “drug targeting”). (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The development of optimised tolerance-inducing nanoparticles (“OpToPas”) with improved functional and tolerability profile to bring disease-inducing antigens via the bloodstream to the LSECs (so-called “drug targeting”). (English) / qualifier | |||||||||||||||
point in time: 24 October 2021
| |||||||||||||||
Revision as of 17:34, 24 October 2021
Project Q3303676 in Germany
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3303676 in Germany |
Statements
234,573.04 Euro
0 references
1 October 2017
0 references
30 September 2019
0 references
Universitätsklinikum Hamburg-Eppendorf (Öffentlich-rechtliche Körperschaft)
0 references
20251
0 references
Die Entwicklung von optimierten toleranz-induzierenden Nanopartikeln ("OpToPas") mit verbessertem Funktions- und Verträglichkeitsprofil um krankheitsauslösende Antigene über die Blutbahn zu den LSECs zu bringen (sog. "Drug Targeting"). (German)
0 references
The development of optimised tolerance-inducing nanoparticles (“OpToPas”) with improved functional and tolerability profile to bring disease-inducing antigens via the bloodstream to the LSECs (so-called “drug targeting”). (English)
24 October 2021
0 references
Identifiers
DE_TEMPORARY_6474
0 references